UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52

Benzinga · 2d ago
UBS analyst Joon Lee initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating and announces Price Target of $52.